A market research release counts 22+ sleep apnea drugs in development and notes Zepbound's December 2024 FDA approval for obesity with moderate-to-severe OSA.
Recap by typeshit. Full story at The Manila Times.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
Reuters reports Lilly stock climbed to a new peak Thursday as its blockbuster weight loss shots kept driving sales.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Loading…